TipRanks
Advertisement
Advertisement

DE:YPH Stock Latest News

Is ALPMF a Buy, Before Earnings?
Pre-EarningsIs ALPMF a Buy, Before Earnings?
2M ago
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
PremiumThe Fly
Sangamo files for restructuring, plans asset sales to Lilly, Astellas
3M ago
LLY
SGMO
Astellas Pharma Cuts Director Slate After Outside Director Resigns
PremiumCompany Announcements
Astellas Pharma Cuts Director Slate After Outside Director Resigns
4M ago
Astellas Launches Five-Year CSP2026 Plan Targeting Pipeline-Led Record Revenues
PremiumCompany Announcements
Astellas Launches Five-Year CSP2026 Plan Targeting Pipeline-Led Record Revenues
4M ago
Astellas Extends Global Performance-Linked Stock Incentives for Executives
PremiumCompany Announcements
Astellas Extends Global Performance-Linked Stock Incentives for Executives
5M ago
Astellas Extends Performance-Linked Stock Incentive Plan for Directors in FY2026
PremiumCompany AnnouncementsAstellas Extends Performance-Linked Stock Incentive Plan for Directors in FY2026
5M ago
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
Premium
Ratings
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
5M ago
Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results
Premium
Company Announcements
Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results
5M ago
Astellas Pharma Announces New Board Slate and Governance Changes for 2026
PremiumCompany Announcements
Astellas Pharma Announces New Board Slate and Governance Changes for 2026
5M ago
Is ALPMF a Buy, Before Earnings?
PremiumPre-Earnings
Is ALPMF a Buy, Before Earnings?
5M ago
Astellas Highlights R&D Strategy While Flagging Market and Development Risks
PremiumCompany Announcements
Astellas Highlights R&D Strategy While Flagging Market and Development Risks
6M ago
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
PremiumCompany Announcements
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
7M ago
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
PremiumCompany AnnouncementsAstellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
7M ago
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
Premium
Company Announcements
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
8M ago
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
Premium
Ratings
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
8M ago
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
PremiumCompany Announcements
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
8M ago
ALPMF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ALPMF Upcoming Earnings Report: What to Expect?
8M ago
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
PremiumCompany Announcements
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
10M ago
Astellas Pharma Revises FY2025 Financial Forecasts Upward
PremiumCompany Announcements
Astellas Pharma Revises FY2025 Financial Forecasts Upward
11M ago
Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
PremiumPre-EarningsAstellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
11M ago
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
Premium
Company Announcements
Astellas Pharma’s GLEAM Trial Falls Short of Primary Endpoint in Pancreatic Cancer Study
12M ago
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
Premium
Company Announcements
Astellas Pharma’s IZERVAY Gains Conditional Approval in Japan for Geographic Atrophy
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >